Biliary pharmacodynamic exposure to linezolid in two liver transplant patients

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 2, 2014, Pages 567-568

  Pea, Federico ^a,b   Lugano, Manuela ^b   Baccarani, Umberto ^b   Della Rocca, Giorgio ^b   Viale, Pierluigi ^c  

^a SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^b UNIVERSITY OF UDINE   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Bile; Enterococcus; Pharmacodynamics; Pharmacokinetics

Indexed keywords

ASPARTATE AMINOTRANSFERASE; CREATININE; LACTIC ACID; LINEZOLID;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILE; BLOOD SAMPLING; CASE REPORT; CHOLANGITIS; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG MONITORING; DRUG TOLERABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERLACTATEMIA; LACTATE BLOOD LEVEL; LETTER; LIVER GRAFT; LIVER TRANSPLANT PATIENT; MALE; MINIMUM INHIBITORY CONCENTRATION; PATIENT; PLASMA CONCENTRATION-TIME CURVE; VANCOMYCIN RESISTANT ENTEROCOCCUS;

BILE; ENTEROCOCCUS; PHARMACODYNAMICS; PHARMACOKINETICS;

ACETAMIDES; BILE; BIOLOGICAL MARKERS; HUMANS; LIVER TRANSPLANTATION; OXAZOLIDINONES;

EID: 84892468441     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt382     Document Type: Letter

References (11)

1. Asín E, Isla A, Canut A et al. Comparison of antimicrobial pharmacokinetic/pharmacodynamic breakpoints with EUCAST and CLSI clinical breakpoints for Gram-positive bacteria. Int J Antimicrob Agents 2012; 40: 313-22.
2. Kwon W, Jang JY, Kim EC et al. Changing trend in bile microbiology and antibiotic susceptibilities: over 12 years of experience. Infection 2013; 41:93-102.
3. Patel G, Snydman DR. Vancomycin-resistant Enterococcus infections in solid organ transplantation. Am J Transplant 2013; 13 Suppl 4: 59-67.
4. Cremaschi E, Maggiore U, Maccari C et al. Linezolid levels in a patient with biliary tract sepsis, severehepatic failureandacutekidney injuryonsustained low-efficiency dialysis (SLED). Minerva Anestesiol 2010; 76: 961-4.
5. Pea F, Viale P, Lugano M et al. Biliary penetration and pharmacodynamic exposure of linezolid in liver transplant patients. J Antimicrob Chemother 2009; 63: 167-9.
6. Rayner CR, Forrest A, Meagher AK et al. Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin Pharmacokinet 2003; 42: 1411-23.
7. Pea F, Viale P, LuganoMet al. Linezolid disposition after standard dosages in critically ill patients undergoing continuous venovenous hemofiltration: a report of 2 cases. Am J Kidney Dis 2004; 44: 1097-102.
8. Pea F, Furlanut M, Cojutti P et al. Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis. Antimicrob Agents Chemother 2010;54: 4605-10.
9. Radunz S, Juntermanns B, Kaiser GM et al. Efficacy and safety of linezolid in liver transplant patients. Transpl Infect Dis 2011; 13: 353-8.
10. Pea F, Viale P, Cojutti P et al. Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients. J Antimicrob Chemother 2012; 67: 2034-42.
11. Tanaka A, Takada T, Kawarada Y et al. Antimicrobial therapy for acute cholangitis: Tokyo Guidelines. J Hepatobiliary Pancreat Surg 2007; 14: 59-67.